Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in...

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Dopamine agonists are hypothesized to treat major depressive disorder (MDD) by influencing ventrostriatal dopamine and reward function.
• A key question is whether these treatments are most effective for patients with pre-existing reward processing deficits.

Purpose of the Study:

• To investigate if measures of reward processing and ventrostriatal dopamine function predict treatment response to the dopamine agonist pramipexole in MDD.
• To explore the relationship between baseline reward system function and clinical outcomes in depressed patients treated with pramipexole.

Main Methods:

• Assessed reward learning behavior and ventrostriatal prediction error signaling using functional MRI in individuals with MDD and healthy controls.
• Measured ventrostriatal dopamine release using 11C-(+)-PHNO PET scans before and after amphetamine administration.
• Administered open-label pramipexole to the MDD group for 6 weeks, assessing symptom changes and reassessing reward learning post-treatment.

Main Results:

• Depressed individuals showed lower baseline reward learning and trends towards blunted reward prediction error signaling and increased dopamine release compared to controls.
• Pramipexole treatment led to significant symptom improvements in the MDD group.
• Contrary to hypotheses, stronger baseline reward learning and prediction error signaling, along with lower baseline D2/3 receptor availability and dopamine release, predicted greater symptom improvement.

Conclusions:

• Baseline reward-related mesolimbic dopamine function may identify depressed individuals likely to respond to dopaminergic pharmacotherapy.
• The findings suggest that dopaminergic treatments might be more effective in patients with robust, rather than deficient, baseline reward processing.
• Further replication is needed, but these results offer potential biomarkers for predicting pramipexole response in MDD.